BMRA Stock News & Analysis | Latest Updates

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use

(NASDAQ:BMRA) IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved its Fortel® Kidney Test for home use. This important regulatory milestone expands access to accurate, easy-to-use diagnostic tools supporting early identification of kidney damage in high-risk populations.

September 3, 2025Regulation

BMRA News

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use

Biomerica's inFoods IBS Test Featured In Prestigious Journal Gastroenterology As Landmark Peer-Reviewed Study Demonstrates Symptom Improvement In IBS Patients Through Personalized, Non-Drug Dietary Therapy

Biomerica Announces Real-World Results Showing Effectiveness Of inFoods IBS Product, Along With Launch Of Proprietary Real-Time Patient Feedback System To Enhance Symptom Tracking And Improve Patient Outcomes

Announces The Co And Its CLIA Laboratory Partner Have Submitted An Application To The American Medical Association CPT Editorial Panel Requesting The Assignment Of A Proprietary Laboratory Analysis Code For The InFoods IBS Diagnostic Test

Biomerica's Fortel Ulcer Test Approved For Sale In UAE, Enabling Rapid 10-Minute Detection Of Helicobacter pylori, A Class 1 Carcinogen Linked To 80% Of Gastric Cancer Cases—Offering Fast, Accessible Diagnostic Tool Amid Growing Regional GI Health Concern

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

UAE Ministry of Health and Prevention Approves Biomerica's Fortel Kidney Disease Test For Sale

Crude Oil Moves Higher; Travelers Earnings Beat Estimates

Biomerica Announces 1-For-8 Reverse Stock Split

Biomerica Q3 EPS $(0.06) Up From $(0.11) YoY, Sales $1.12M Up From $1.02M YoY

Biomerica's Food Intolerance Tests For Crohn's Disease And Ulcerative Colitis Receive IVDR Certification In EU

Biomerica inFoods IBS Announces Personalized Diet Therapy Reduces Abdominal Pain, Bloating In IBS Patients; Clinical Trial Shows Greater Improvement Than Sham Diet

Watching Biomerica; Co Named In 'Research Shows Blood Test May Provide Personalized Dietary Therapy For Patients With Irritable Bowel Syndrome'; Michigan Medicine And Cleveland Clinic Study Finds Blood Test-Guided Diet Reduces Abdominal Pain In IBS Patien

Biomerica Q2 2025 Revenue $1.64M Vs $1.57M YoY; EPS $(0.06) Vs $(0.09) YoY

Biomerica shares are trading higher. The company reported Q2 financial results.

12 Health Care Stocks Moving In Friday's After-Market Session